AIRR - ANZCA Institutional Research Repository
Skip navigation
Please use this identifier to cite or link to this item: https://hdl.handle.net/11055/35
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAngus, JA-
dc.contributor.authorSoeding, PF-
dc.contributor.authorHughes, RJA-
dc.contributor.authorWright, CE-
dc.date2017-03-11-
dc.date.accessioned2017-11-09T01:29:30Z-
dc.date.available2017-11-09T01:29:30Z-
dc.date.issued2017-06-
dc.identifier.citationAngus JA, Soeding PF, Hughes RJA, Wright CE. Functional estimation of endothelin-1 receptor antagonism by bosentan, macitentan and ambrisentan in human pulmonary and radial arteries in vitro. Eur J Pharmacol. 2017; 804:111-116.en_US
dc.identifier.issn0014-2999en_US
dc.identifier.urihttp://hdl.handle.net/11055/35-
dc.description.abstractEndothelin receptor antagonists are approved for pulmonary arterial hypertension. Development of selective ETA-receptor antagonists over mixed or dual receptor antagonists has depended on a range of receptor binding assays, second messenger assays and functional blood vessel assays. This study compared the 3 clinically-approved endothelin receptor antagonists in assays of human isolated pulmonary and radial arteries in vitro. METHODS: Human isolated pulmonary (i.d. 5.5mm) and human radial (i.d. 3.23mm) artery ring segments were mounted in organ baths for isometric force measurement. Single concentration-contraction curves to endothelin-1 were constructed in the absence or presence of bosentan (1-10µM), macitentan (0.03-0.3µM) or ambrisentan (0.1-1µM). RESULTS: All 3 endothelin antagonists caused competitive rightward shifts in the endothelin-1 concentration-response curves in both arteries. The Clark plot and analysis gave the following pKB values: bosentan, pulmonary artery 6.28±0.13 and radial artery 6.04±0.10; macitentan, pulmonary artery 8.02±0.13 and radial artery 7.49±0.08; and ambrisentan, pulmonary artery 7.38±0.13 and radial artery 6.96±0.10. CONCLUSIONS: Noting the maximum plasma levels attained from recommended oral doses of each antagonist in volunteers, the pKB findings here show that there would be significant antagonism of endothelin-1 contraction in the pulmonary and radial arteries at therapeutic plasma levels. This functional assay confirms in human tissue that much higher plasma concentrations of endothelin-1 receptor antagonists are required to be effective than those predicted from binding or other biochemical assays.en_US
dc.subjectBosentanen_US
dc.subjectEndothelin-1en_US
dc.subjectmacitentanen_US
dc.subjectambrisentanen_US
dc.subjectHuman pulmonary arteryen_US
dc.subjectHuman radial arteryen_US
dc.titleFunctional estimation of endothelin-1 receptor antagonism by bosentan, macitentan and ambrisentan in human pulmonary and radial arteries in vitroen_US
dc.typeJournal Articleen_US
dc.type.contentTexten_US
dc.identifier.journaltitleEuropean journal of pharmacologyen_US
dc.identifier.doi10.1016/j.ejphar.2017.03.014en_US
dc.description.affiliatesAustralian and New Zealand College of Anaesthetistsen_US
dc.description.pubmedurihttps://www.ncbi.nlm.nih.gov/pubmed/28300593en_US
dc.ispartof.anzcaresearchfoundationYes-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
Appears in Collections:Scholarly and Clinical
Show simple item record

Page view(s)

202
checked on May 10, 2025

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.